8-K: CG Oncology Announces Positive Clinical Trial Results and Provides Business Update

CG Oncology reported positive results from its CORE-001 and BOND-003 studies, highlighting the potential of cretostimogene as a bladder-sparing therapy for bladder cancer, and provided a business update.

Summary

• CG Oncology announced its second quarter 2024 financial results and provided business updates, including positive clinical trial results for its lead drug candidate, cretostimogene.
• The CORE-001 study, evaluating cretostimogene in combination with pembrolizumab, showed a 54% complete response rate at the 24-month landmark in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC).
• The BOND-003 study, evaluating cretostimogene monotherapy, demonstrated a 75.2% complete response rate at any time in patients with BCG-unresponsive HR-NMIBC.
• The company initiated an Expanded Access Program for cretostimogene in June, with the first patient already dosed.
• CG Oncology's cash position was $552.9 million as of June 30, 2024, and the company expects this to fund operations through 2027.
• Research and development expenses for the second quarter were $18.5 million, compared to $9.8 million in the same period last year.
• General and administrative expenses increased to $7.5 million from $2.5 million in the prior year's second quarter.
• The net loss for the quarter was $18.9 million, or ($0.28) per share, compared to a net loss of $11.6 million, or ($3.93) per share, in the second quarter of 2023.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strong cash position, indicating a favorable outlook for the company. The increase in expenses is a minor concern, but the overall tone is optimistic.

Positives

• The 54% complete response rate in the CORE-001 study at 24 months is a positive outcome for the combination therapy.
• The 75.2% complete response rate in the BOND-003 study indicates strong efficacy for cretostimogene monotherapy.
• The 100% progression-free survival at 24 months in the CORE-001 study is a significant positive.
• The initiation of the Expanded Access Program provides patients with early access to cretostimogene.
• The company's strong cash position provides financial stability and runway through 2027.

Negatives

• The net loss for the second quarter of 2024 was $18.9 million, which is higher than the $11.6 million loss in the same quarter of 2023.
• Research and development expenses have increased significantly, from $9.8 million to $18.5 million year-over-year.
• General and administrative expenses have also increased substantially, from $2.5 million to $7.5 million year-over-year.

Risks

• Clinical trial results may change as patient enrollment continues and more data becomes available.
• There may be potential delays in the commencement, enrollment, and completion of clinical trials.
• The company may use its capital resources sooner than expected, and they may be insufficient to achieve anticipated milestones.
• The company is dependent on third parties for manufacturing, shipping, and clinical testing.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and/or commercialization.

Future Outlook

The company anticipates sharing primary results from the BOND-003 registrational study of cretostimogene monotherapy by the end of 2024 and progressing toward submitting its Biologics License Application. They also expect their cash runway to be sufficient to fund operations through 2027.

Management Comments

• Arthur Kuan, Chairman & Chief Executive Officer of CG Oncology, stated that the data presented at AUA and ASCO affirmed the potential for cretostimogene to be used as a bladder-sparing backbone therapy for NMIBC.
• Mr. Kuan also mentioned that the company demonstrated its commitment to bladder cancer patients by initiating the Expanded Access Program in June and were encouraged by the strong enrollment.

Industry Context

This announcement is significant in the context of the bladder cancer treatment landscape, where there is a need for effective bladder-sparing therapies. The positive results from the CORE-001 and BOND-003 studies position cretostimogene as a potential competitor to existing treatments and a potential new standard of care for BCG-unresponsive NMIBC.

Comparison to Industry Standards

• The 54% complete response rate at 24 months in the CORE-001 study is competitive with other combination therapies in the NMIBC space, such as those involving checkpoint inhibitors.
• The 75.2% complete response rate in the BOND-003 study is notably high compared to historical data for BCG-unresponsive NMIBC, where monotherapy options have often shown lower efficacy.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) have established checkpoint inhibitors as a standard of care in various cancers, and CG Oncology's combination approach with pembrolizumab is a direct comparison.
• Other companies developing oncolytic viruses for bladder cancer include companies like VBL Therapeutics, however, CG Oncology's results appear to be leading the field in terms of efficacy.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the company's financial stability.
• Patients with bladder cancer may benefit from the potential approval of cretostimogene as a new treatment option.
• Employees may be encouraged by the company's progress and growth.

Next Steps

• The company will share primary results from the BOND-003 registrational study by the end of 2024.
• CG Oncology will progress toward submitting its Biologics License Application for cretostimogene.

Key Dates

Keywords

Cretostimogene, Bladder Cancer, NMIBC, Oncolytic Immunotherapy, Clinical Trial, Pembrolizumab, BOND-003, CORE-001, Expanded Access Program, Complete Response, HR-NMIBC